Results 21 to 30 of about 51,089 (251)

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure
Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
doaj   +2 more sources

Cardiac myosin inhibitors: Efficacy, safety and future directions of aficamten in hypertrophic obstructive cardiomyopathy

The Egyptian Heart Journal
Background Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects the cardiac myocytes leading to asymmetric hypertrophy of the left ventricle and obstruction of the left ventricular outflow tract (LVOT) with possible risk of ...
Ikponmwosa Jude Ogieuhi, Victor Oluwatomiwa Ajekiigbe, Boluwaduro Abasiekem Adeyemi, Bright Nwatamole, Komolafe Babajide Ayodeji, Oshomoh Mark-Anthony Ugiomoh, Temiloluwa Adebayo Odeniyi, Adewunmi Akingbola, Efosa Peace Iyawe, Olabode Olawale Oladejo, Motunrayo Oluwatoyosi Lawal, Nathnael Abera Woldehana, Ifeoluwa Sandra Bakare, Adejumo Temilade Patience, Grace Chinenye Okoro   +14 more
doaj   +3 more sources

A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants. [PDF]

JACC Basic Transl Sci, 2022
Malik FI, Robertson LA, Armas DR, Robbie EP, Osmukhina A, Xu D, Li H, Solomon SD.   +7 more
europepmc   +2 more sources

Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM

Journal of Education, Health and Sport
Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Robert Bujak   +3 more
doaj   +2 more sources

Discovery of a novel cardiac-specific myosin modulator using artificial intelligence-based virtual screening

Nature Communications, 2023
Direct modulation of cardiac myosin function has emerged as a therapeutic target for both heart disease and heart failure. However, the development of myosin-based therapeutics has been hampered by the lack of targeted in vitro screening assays.
Priyanka Parijat, Seetharamaiah Attili, Zoe Hoare, Michael Shattock, Victor Kenyon, Thomas Kampourakis   +5 more
doaj   +1 more source

Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy

Scientific Reports, 2023
Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease in humans and cats and lacks efficacious pharmacologic interventions in the preclinical phase of disease.
Ashley N. Sharpe, Maureen S. Oldach, Victor N. Rivas, Joanna L. Kaplan, Ashley L. Walker, Samantha L. Kovacs, Darren T. Hwee, Peadar Cremin, Bradley P. Morgan, Fady I. Malik, Samantha P. Harris, Joshua A. Stern   +11 more
doaj   +1 more source

Activin-A and Bmp4 Levels Modulate Cell Type Specification during CHIR-Induced Cardiomyogenesis [PDF]

, 2015
The use of human pluripotent cell progeny for cardiac disease modeling, drug testing and therapeutics requires the ability to efficiently induce pluripotent cells into the cardiomyogenic lineage.
Blinka, Steven, Gundry, Rebekah, Horst, Audrey, Kim, Min-Su, Lough, John, Mahnke, Donna K., Schuman, James, Stamm, Karl D., Tomita-Mitchell, Aoy   +8 more
core   +15 more sources

Development and prevention of ischemic contracture (“stone heart”) in the pig heart

Frontiers in Cardiovascular Medicine, 2023
Stone heart (ischemic contracture) is a rare and serious condition observed in the heart after periods of warm ischemia. The underlying mechanisms are largely unknown and treatment options are lacking.
Mei Li, Mei Li, Zhi Qin, Erik Steen, Ann Terry, Bowen Wang, Björn Wohlfart, Stig Steen, Anders Arner   +8 more
doaj   +1 more source

Cycling Cross-Bridges Contribute to Thin Filament Activation in Human Slow-Twitch Fibers

Frontiers in Physiology, 2020
It has been shown that not only calcium but also strong binding myosin heads contribute to thin filament activation in isometrically contracting animal fast-twitch and cardiac muscle preparations. This behavior has not been studied in human muscle fibers
Alfredo Jesus López-Dávila, Joseph M. Chalovich, Stefan Zittrich, Birgit Piep, Faramarz Matinmehr, Andras Málnási-Csizmadia, Anna Á. Rauscher, Theresia Kraft, Bernhard Brenner, Robert Stehle   +9 more
doaj   +1 more source

Angiotensin II Facilitates Matrix Metalloproteinase-9-Mediated Myosin Light Chain Kinase Degradation in Pressure Overload-Induced Cardiac Hypertrophy

Cellular Physiology and Biochemistry, 2017
Background/Aims: Angiotensin II (Ang II) has been shown to promote cardiac remodeling during the process of hypertrophy. Myosin light chain kinase (MLCK), a specific kinase for the phosphorylation of myosin light chain 2 (MLC2), plays an important role ...
Shun Wang, Mian Cheng, Zhengqing Hu, Shan Hu, Qiang Zou, Xin Lai, Beilei Liu, Hong Jiang, Congxin Huang, Gang Wu   +9 more
doaj   +1 more source